Roivant Sciences Q1 2024 Earnings Report
Key Takeaways
Roivant reported positive data from the chronic period of the Phase 2b study of RVT-3101 in ulcerative colitis and from the ADORING 1 trial evaluating VTAMA in patients with atopic dermatitis. The company initiated the TAHOE Phase 2 study of RVT-3101 in Crohn’s disease and the Phase 1 study of IMVT-1402 in healthy volunteers. VTAMA net product revenue was $16.7M for the quarter. Roivant's consolidated cash, cash equivalents and restricted cash was $1.4B at June 30, 2023.
RVT-3101 showed improved efficacy in the TUSCANY-2 Phase 2b study for ulcerative colitis.
The first patient was dosed in the TAHOE study, a Phase 2 trial of RVT-3101 in Crohn’s disease.
VTAMA net product revenue reached $16.7M for the quarter ended June 30, 2023.
Roivant's cash, cash equivalents and restricted cash totaled $1.4B as of June 30, 2023.
Roivant Sciences
Roivant Sciences
Forward Guidance
Roivant anticipates several key milestones in the coming quarters, including regulatory submissions and clinical trial results.
Positive Outlook
- Dermavant plans to submit its sNDA for VTAMA in atopic dermatitis to the FDA in Q1 2024.
- Immunovant expects IMVT-1402 Phase 1 initial data in September, October or November 2023.
- Telavant expects data from the induction portion of the Phase 2 study of RVT-3101 in Crohn’s disease in Q4 2024.
- Priovant plans to announce topline results from the trial evaluating brepocitinib for SLE in Q4 2023.
- Hemavant plans to announce data from the trial evaluating RVT-2001 for transfusion-dependent anemia in MDS patients in H2 2023.
Challenges Ahead
- The document does not explicitly state any negative forward guidance.
- The document does not explicitly state any negative forward guidance.
- The document does not explicitly state any negative forward guidance.
- The document does not explicitly state any negative forward guidance.
- The document does not explicitly state any negative forward guidance.